Login to Your Account



Financings Roundup

Adnexus Files For $86M IPO; Funds For Adnectin Pipeline

By Jennifer Boggs


Thursday, August 23, 2007
On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription